Fibrin Glue Market Size and Share Report – Global Growth, Development, & Demand Forecast to 2030

Fibrin Glue Market Overview

The global fibrin glue market was valued at USD 43.8 Billion (E) in 2023, and it will grow at a rate of 6.2% during 2024–2030, to reach USD 65.7 Billion in 2030.

Fibrin glue is a hemostatic agent utilized for the closing of tissue during operations. This surgical glue aids in decreasing blood loss during operations and in wound management. The product imitates the later stages of natural hemostasis, to form a fibrin clot. The utilization of fibrin glue can also decrease postoperative and perioperative problems, by decreasing fluid and air leakage and preventing fistula development. These sealants have a unique physiological action, and the resultant clot is fully degraded by the body's natural wound-curing procedure after the blood vessel seals itself underneath.

Fibrin glues currently find applications in many surgical specialties, such as cardiovascular, urological, pulmonary, wound management, orthopedic, ophthalmic, neurosurgery, plastics & reconstruction, and dental.

Market Dynamics

The industry size is witnessing an upswing because of the rising aging populace prone to chronic ailments. Moreover, the surge in the occurrence of gastric diseases, atherosclerosis, ischemic strokes, aneurysms, tumors, blood clots in the brain, cancer, myocardial infarction, arrhythmia, and obstructions in the blood vessels of the liver, heart, kidneys, and brain has resulted in an augmenting demand for surgical procedures. The growth in the incidence of sports wounds and road accidents further contributes to the need for fibrin glue, thus contributing to industry development.

For example, 2020 saw an occurrence rate of approximately 190 heart attacks per 10,000 individuals over 85 years old and around 117 for those aged 75–84. Moreover, as per the American College of Cardiology, more than 795,000 individuals in the U.S. suffer from a stroke yearly. Additionally, the increase in the number of general operations, cardiovascular operations, central nervous system operations, cosmetic operations, orthopedic surgeries, and ophthalmic operations drives the development of the fibrin glues industry. In the U.S., the American Society for Metabolic and Bariatric Surgery reported 268,000 bariatric operations in 2020 alone.

Moreover, the advancements in technology, product launches, and strategic initiatives of key companies, including research projects, acquisitions, and collaborations, are driving the expansion of the fibrin glue market. An example is Grifols' introduction of the plasma protein-based VISTASEAL, a fibrin sealant designed for surgical bleeding control. VISTASEAL emulates the clot creation procedure, creating a fast, adherent, and tough clot, irrespective of the patient's coagulation profile.

The growing count of complex cardiac surgeries throughout the world, credited to the increasing occurrence of cardiac illnesses in emerging economies, will contribute to the rising acceptance of hemostats during the projection period. The utilization of fibrin glues enhances patient outcomes, reduces complications, and lowers the risk of mortality from exsanguination. Moreover, the advantage of fibrin glues over conservative approaches, such as cauterization and suturing, would lead to the growth of the market.

Explore more about this report - Request free sample

Segmentation Analysis

Based on application, the cardiovascular surgery category is generating the highest revenue.

• Heart diseases are the largest killer in the world, leading to around 18 million deaths each year.

These diseases could involve abnormal heart rhythms, structural deformities in the heart, or blockage of the blood vessels. Therefore, with an increasing number of people suffering from heart diseases, the number of corrective and diagnostic surgeries continues to rise.

On the basis of end user, the hospitals category is projected to lead the fibrin glue industry during the projection period. The growing count of CABG and other cardiovascular operations in hospitals is expected to propel the category during the projection period.

• As per the latest American Hospital Association survey, 6,129 hospitals in the U.S., which totaled 919,649 beds, received over 34 million in-patients in 2023.

Hospitals are the primary choice of patients for open surgeries as these places are trusted to have all the necessary tools and professionals to handle such risky procedures.

Based on type, the liquid category is projected to lead the fibrin glue industry, credited to the advanced procedural results with liquid fibrin glue in comparison to other patches. Furthermore, their advanced rational stability and fast action propel this category.

Moreover, the patch category is predicted to witness significant growth in revenue generation over this decade. One of the key benefits of a fibrin glue patch is that it can attain hemostasis within 4–5 minutes of application.

Geographical Insights

The fibrin glue market in the APAC region is projected to experience the highest CAGR over the projection period. The growing expenditure by key healthcare companies in this continent, increasing health awareness, rising disposable income, growing medicinal tourism industry, existence of less-severe guidelines for the players, and rising demand for superior healthcare are projected to propel the development of this industry during the projection period.

Moreover, the North American market, which is the biggest in the world currently, is projected to witness significant growth.

• This would be due to a sharp rise in the number of surgeries and a strong focus on embracing minimally invasive procedures.
• Additionally, the presence of all major market players, supportive insurance reimbursement guidelines, high disposable income, rising incidence of life-threatening diseases and severe injuries, and overall growing volume of surgeries drive the market here.

Top Fibrin Glue Producers:

• 3S Corporation
• Baxter International Inc.
• Bayer AG
• Becton, Dickinson and Company
• CSL Behring
• Artivion Inc
• Dolphin Pharmaceutical Limited
• Harvest Technology Group Pty Limited
• Johnson & Johnson Services Inc.
• Shanghai RAAS Blood Products Co. Ltd.
• STB Lifesaving Technologies
• Zimmer Biomet Holdings Inc.
• Takeda Pharmaceuticals Company Limited
• Vivostat A/S
• Mallinckrodt plc